| P50 | author | Nusrat Husain | Q40160167 |
| | Bill Deakin | Q43291499 |
| | Jaime Eduardo Cecilio Hallak | Q89090861 |
| P2093 | author name string | Serdar Dursun | |
| | Paul Richardson | |
| | Graham Dunn | |
| | Fareed Minhas | |
| | Imran B Chaudhry | |
| | John Stirling | |
| P2860 | cites work | NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development | Q28205016 |
| | A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia | Q28263942 |
| | N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial | Q28277707 |
| | Association of schizophrenia and autoimmune diseases: linkage of Danish national registers | Q28300105 |
| | The positive and negative syndrome scale (PANSS) for schizophrenia | Q28301751 |
| | Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. | Q33814201 |
| | A separate disease within the syndrome of schizophrenia | Q34140437 |
| | Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. | Q34174069 |
| | Antipsychotic drug effects on brain morphology in first-episode psychosis | Q34408860 |
| | Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. | Q34574117 |
| | Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. | Q34584573 |
| | Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison | Q34606845 |
| | Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. | Q34696376 |
| | Amoxapine as an antipsychotic: comparative study versus haloperidol | Q34713797 |
| | Glutamate receptor dysfunction and schizophrenia | Q34719075 |
| | Neuroprotection by tetracyclines | Q35941699 |
| | Schizophrenia: new pathological insights and therapies | Q36563424 |
| | Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review | Q37001984 |
| | IQ as a predictor of functional outcome in schizophrenia: a longitudinal, four-year study of first-episode psychosis | Q37074624 |
| | Calprotectin in microglia from frontal cortex is up-regulated in schizophrenia: evidence for an inflammatory process? | Q40182384 |
| | Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia | Q40214962 |
| | The NADPH oxidase NOX2 controls glutamate release: a novel mechanism involved in psychosis-like ketamine responses | Q42925757 |
| | Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). | Q43219125 |
| | Chronic administration of haloperidol and olanzapine attenuates ketamine-induced brain metabolic activation | Q44355547 |
| | Minocycline as adjunctive therapy for schizophrenia: an open-label study | Q46330964 |
| | Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia | Q46659291 |
| | First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients | Q46724711 |
| | Inhibition of thrombin-induced microglial activation and NADPH oxidase by minocycline protects dopaminergic neurons in the substantia nigra in vivo | Q46747415 |
| | Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study | Q48258798 |
| | Brain volume changes in the first year of illness and 5-year outcome of schizophrenia. | Q48407980 |
| | Baseline neurocognitive deficits in the CATIE schizophrenia trial. | Q50732363 |
| | The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance | Q52112284 |
| | Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. | Q53411974 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| | placebo | Q269829 |
| | minocycline | Q415336 |
| P304 | page(s) | 1185-93 | |
| P577 | publication date | 2012-09-01 | |
| P1433 | published in | Journal of Psychopharmacology | Q6295819 |
| P1476 | title | Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment | |
| P478 | volume | 26 | |